Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 2 papers. Top paper: “First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies”.
Minal Barve, Devalingam Mahalingam, Jay Parekh, Michael R. Kurman, James Strauss +10 more
Darleen Lessard, Jay Parekh, Mayra Tisminetzky, Joel M. Gore, Jorge Yarzebski +4 more